Health and Healthcare
5864 Articles
A new report from the biotech team at Stifel focuses on catalysts from companies that are presenting at the firm's…
Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.
Providing care for a parent or loved one with Alzheimer's disease or other dementia costs $20,000 or more for 42%…
On Monday, Sunesis made an announcement that it would be making a presentation regarding its drug candidates vosaroxin and cytarabine.
Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.
Juno Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize…
ReWalk Robotics reported quarterly earnings Thursday morning for the first time since the company's initial public offering in mid-September.
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand…
Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble…
A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation…
Dendreon has committed the ultimate sin by filing for bankruptcy protection.
Humana reported disappointing third-quarter 2014 results before markets opened Friday morning.
Our top personal finance-related articles today. Your wallet will thank you later.